-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Benzinga·09/09/2026 12:10:11
Listen to the news
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.